{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:04:10Z","timestamp":1782486250927,"version":"3.54.5"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapse remains the leading cause of failure after allogeneic stem cell transplantation (allo-SCT) for hematologic malignancies. Donor lymphocyte infusion (DLI), the infusion of lymphocytes from the original stem cell donor, was introduced in the late 1980s as a strategy to prevent or treat relapse by augmenting the graft-versus-leukemia (GvL) effect. Over time, DLI has been used in various settings: initially as therapeutic DLI for overt relapse and later as preemptive DLI, administered in response to early signs of relapse, such as persistent or recurrent measurable residual disease (MRD), or as prophylactic DLI to mitigate high relapse risk before clinical relapse occurs (see Visual Abstract). However, questions remain regarding how, when, and in whom DLI is best deployed, reflecting ongoing controversy and heterogeneity in clinical practice. A recent survey of 165 European Society for Blood and Marrow Transplantation centers across 43 countries reported that DLI was used prophylactically for high-risk hematologic diseases in 43.8% of these centers. DLI was used preemptively for MRD positivity in 86.9% of centers and for mixed chimerism in 73.1%. Therapeutic DLI was administered for hematologic relapse in 73.1% of centers. Active graft-versus-host disease and active infections were considered absolute contraindications by 85.6% and 57.5% of the centers, respectively. This observed variability in center practices underscores the need to clarify the \u201cwho, when, and why\u201d of posttransplant cellular interventions. In this review, we explore DLI strategies and the potential sequencing with novel targeted therapies across prophylactic, preemptive, and therapeutic applications, illustrated through case examples in patients with acute myeloid leukemia. We highlight findings from retrospective, as well as the scarce prospective studies and extend considerations to other indications, including chronic myeloid leukemia, myelofibrosis, and acute lymphoblastic leukemia. Additionally, we review emerging combination strategies with targeted therapies across different hematologic malignancies and adoptive cell therapies beyond conventional DLI.<\/jats:p>","DOI":"10.1182\/hematology.2025000747","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:49Z","timestamp":1764943789000},"page":"537-546","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD"],"prefix":"10.1182","volume":"2025","author":[{"given":"Pleun","family":"Schonewille","sequence":"first","affiliation":[{"name":"1 Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"van Rhenen","sequence":"additional","affiliation":[{"name":"1 Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske MT ten","family":"Ham","sequence":"additional","affiliation":[{"name":"2 Department of Epidemiology & Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniek","family":"de Witte","sequence":"additional","affiliation":[{"name":"1 Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[{"name":"1 Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"8","key":"2025120616344359300_hem2025000747C1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41568-025-00830-x","article-title":"Disrupting the balance between activating and inhibitory receptors of \u03b3\u03b4T cells for effective cancer immunotherapy","volume":"25","author":"Beringer","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2025120616344359300_hem2025000747C2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41409-023-01953-1","article-title":"Activity of ex vivo graft and DLI engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party","volume":"58","author":"de Witte","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025120616344359300_hem2025000747C3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/bloodadvances.2020002444","article-title":"\u03b1\u03b2 T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies","volume":"5","author":"de Witte","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2025120616344359300_hem2025000747C4","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"key":"2025120616344359300_hem2025000747C5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/978-3-031-44080-9_59","article-title":"Delayed transfer of immune cells or the art of donor lymphocyte infusion (DLI) 2.0","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Falkenburg","year":"2024"},{"issue":"5","key":"2025120616344359300_hem2025000747C6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025120616344359300_hem2025000747C7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025120616344359300_hem2025000747C8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1172\/JCI86175","article-title":"Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response","volume":"127","author":"van Bergen","year":"2017","journal-title":"J Clin Invest"},{"issue":"9","key":"2025120616344359300_hem2025000747C9","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-023-05276-5","article-title":"The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease","volume":"102","author":"Stadler","year":"2023","journal-title":"Ann Hematol"},{"key":"2025120616344359300_hem2025000747C10","doi-asserted-by":"crossref","first-page":"1335341","DOI":"10.3389\/fimmu.2024.1335341","article-title":"Risk factors for graft- versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation","volume":"15","author":"Koster","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2025120616344359300_hem2025000747C11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025120616344359300_hem2025000747C12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","article-title":"Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study","volume":"59","author":"Yang","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025120616344359300_hem2025000747C13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41409-022-01839-8","article-title":"Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT Cellular Therapy & Immunobiology Working Party","volume":"58","author":"Santoro","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025120616344359300_hem2025000747C14","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41409-021-01232-x","article-title":"Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia","volume":"56","author":"Dunaikina","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025120616344359300_hem2025000747C15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.03.010","article-title":"Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies","volume":"27","author":"Castagna","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2025120616344359300_hem2025000747C16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2025120616344359300_hem2025000747C17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41409-025-02538-w","article-title":"Improved GVHD-free and relapse-free survival after ex vivo \u03b1\u03b2TCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT","volume":"60","author":"Stuut","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2025120616344359300_hem2025000747C18","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"6","key":"2025120616344359300_hem2025000747C19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2025120616344359300_hem2025000747C20","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood.V89.9.3113","article-title":"Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia","volume":"89","author":"Keil","year":"1997","journal-title":"Blood"},{"issue":"5","key":"2025120616344359300_hem2025000747C21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616344359300_hem2025000747C22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025120616344359300_hem2025000747C23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41409-025-02555-9","article-title":"Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT","volume":"60","author":"Santoro","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025120616344359300_hem2025000747C24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00277-023-05093-w","article-title":"Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation","volume":"102","author":"Park","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"2025120616344359300_hem2025000747C25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616344359300_hem2025000747C26","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025120616344359300_hem2025000747C27","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","article-title":"The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era","volume":"26","author":"Schmidt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025120616344359300_hem2025000747C28","doi-asserted-by":"crossref","first-page":"e20191009","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J Exp Med"},{"issue":"1","key":"2025120616344359300_hem2025000747C29","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025120616344359300_hem2025000747C30","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1097\/HS9.0000000000000921","article-title":"Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"2025120616344359300_hem2025000747C31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-022-03352-6","article-title":"FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation","volume":"116","author":"Biavasco","year":"2022","journal-title":"Int J Hematol"},{"key":"2025120616344359300_hem2025000747C32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2017.09.016","article-title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation","volume":"86","author":"Metzelder","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"2025120616344359300_hem2025000747C33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft- versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"18","key":"2025120616344359300_hem2025000747C34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616344359300_hem2025000747C35","first-page":"75","article-title":"Long-term remissions with gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3\/NPM1 mutated acute myeloid leukemia","volume":"7","author":"Tamellini","year":"2024","journal-title":"Blood Cell Ther"},{"issue":"1","key":"2025120616344359300_hem2025000747C36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025120616344359300_hem2025000747C37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2025120616344359300_hem2025000747C38","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv"},{"key":"2025120616344359300_hem2025000747C39","doi-asserted-by":"crossref","first-page":"810387","DOI":"10.3389\/fonc.2021.810387","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2025120616344359300_hem2025000747C40","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1182\/blood-2023-187095","article-title":"Practice patterns of transplant centers regarding maintenance treatment post allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT Acute Leukemia Working Party","volume":"142","author":"Abou Dalle","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025120616344359300_hem2025000747C41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"Jabbour","year":"2024","journal-title":"Blood Cancer J."},{"issue":"11","key":"2025120616344359300_hem2025000747C42","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025120616344359300_hem2025000747C43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41409-024-02475-0","article-title":"The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience","volume":"60","author":"Giammarco","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025120616344359300_hem2025000747C44","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"2025120616344359300_hem2025000747C45","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120616344359300_hem2025000747C46","doi-asserted-by":"crossref","first-page":"12737","DOI":"10.1182\/blood-2022-158191","article-title":"First in human clinical responses and persistence data on TEG001: a next generation of engineered A\u03b2 T cells targeting AML and MM with a high affinity \u03b39\u03b42TCR","volume":"140","author":"de Witte","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025120616344359300_hem2025000747C47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-025-02566-x","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"39","author":"Reinhardt","year":"2025","journal-title":"Leukemia"},{"issue":"103","key":"2025120616344359300_hem2025000747C48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adr0782","article-title":"Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy","volume":"10","author":"Maurer","year":"2025","journal-title":"Sci Immunol"},{"issue":"5","key":"2025120616344359300_hem2025000747C49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.03.409","article-title":"Whole-blood-derived donor lymphocyte infusion: a game-changer for managing chimerism decline in resource-limited settings","volume":"27","author":"Setya","year":"2025","journal-title":"Cytotherapy"},{"issue":"7","key":"2025120616344359300_hem2025000747C50","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"11","key":"2025120616344359300_hem2025000747C51","first-page":"5491","article-title":"Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation","volume":"28","author":"Yu","year":"2020","journal-title":"Support Care Cancer"},{"issue":"10","key":"2025120616344359300_hem2025000747C52","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jval.2020.05.019","article-title":"Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia","volume":"23","author":"Nguyen","year":"2020","journal-title":"Value Health"},{"issue":"10","key":"2025120616344359300_hem2025000747C53","first-page":"1469","article-title":"Cost- effectiveness of gilteritinib for relapsed\/refractory FLT3mut+ acute myeloid leukemia","volume":"27","author":"Pandya","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2025120616344359300_hem2025000747C54","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12288-019-01087-9","article-title":"Haploidentical stem cell transplantation in children with benign disorders: improved survival and cost-effective care over 15 years from a single center in India","volume":"35","author":"Uppuluri","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"2025120616344359300_hem2025000747C55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada","volume":"6","author":"Furzer","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"2025120616344359300_hem2025000747C56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2025120616344359300_hem2025000747C57","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(24)00400-9","article-title":"Urgent need: evidence-based use of donor lymphocyte infusions\u2014authors' reply","volume":"12","author":"Pagliuca","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/537\/2470018\/537schonewille.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/537\/2470018\/537schonewille.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:54Z","timestamp":1765056894000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/537\/556847\/Posttransplant-cells-for-the-win-DLI-and-adoptive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000747","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}